4.4 Review

Targeting the Mevalonate Pathway for Improved Anticancer Therapy

Journal

CURRENT CANCER DRUG TARGETS
Volume 9, Issue 5, Pages 626-638

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800909789057033

Keywords

Mevalonate pathway; protein prenylation; GTP-binding proteins; metastasis; anticancer drug resistance

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [FR1241/3-1, FR1241/5-1]
  2. Wilhelm Sander Stiftung [1999.014.2]
  3. Deutsche Krebshilfe/Dr. Mildred Scheel Stiftung [107361]

Ask authors/readers for more resources

The mevalonate pathway is important for the generation of isoprene moieties, thereby providing the basis for the biosynthesis of molecules required for maintaining membrane integrity, steroid production and cell respiration. Additionally, isoprene precursors are indispensable for the prenylation of regulatory proteins such as Ras and Ras-homologous (Rho) GTPases. These low molecular weight GTP-binding proteins play key roles in numerous signal transduction pathways stimulated upon activation of cell surface receptors by ligand binding. Thus, Ras/Rho proteins eventually regulate cell proliferation, tumor progression and cell death induced by anticancer therapeutics. Lipid modification of Ras/Rho proteins at their C-terminal CAAX-box is essential for their correct intracellular localization and function. Therefore, pharmacological inhibition of the isoprene metabolism is anticipated to impact the manifold biological functions attributed to Ras/Rho proteins. Here, the pros and cons of compounds that interfere with the mevalonate pathway for cancer treatment are summarized and discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available